Pédiatrie Tumeurs solides eSMART European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors. Paris ISABELLE AERTS
Gynécologie - Ovaires YO39523 A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Saint-Cloud
Sein métastatique RH+ CONTESSA - ODO-TE-B301 Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane Saint-Cloud ETIENNE BRAIN
Appareil Digestif EPIC 1511 Impact of Early Palliative Care on Overall Survival of Patients With Metastatic Upper Gastrointestinal Cancers, Treated With First-line Chemotherapy: a Randomized Phase III Trial. Saint-Cloud ELISABETH LUCCHI
Hématologie Myélodysplasie QPL-MDS Evaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS) Saint-Cloud SANDRA MALAK
Appareil Digestif IMMUNO-BIL (D48-1 PRODIGE 57) Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy: a Randomized Non-comparative Two-arm Phase II Study Saint-Cloud
Pédiatrie Tumeurs solides METRO-PD1-1708 Metro-PD1: a phase I/II trial evaluating anti-PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with refractory /relapsing solid tumors or lymphoma Paris ISABELLE AERTS
Appareil Digestif APACaP Multicenter, Randomized Study, Evaluation of Adapted Physical Activity Program in Patients With Unresectable, Locally Advanced or Metastatic Pancreatic Cancer Saint-Cloud
Pédiatrie Tumeurs solides CDRB436G2401 An open label, multi-center roll-over study to assess longterm;effect in pediatric patients treated with Tafinlar;(dabrafenib) and/or Mekinist (trametinib) Paris FRANCOIS DOZ
Pédiatrie Tumeurs solides CRISP (IC 2017-08 / ITCC 053) A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies. Paris ISABELLE AERTS